Higher Systemic Immune-Inflammation Index (SII) Levels Are Associated With Poorer Survival In Immunotherapy-Treated Melanoma Patients
Deniz Can Guven1, Oktay Halit Aktepe1, Hasan Cagri Yildirim1, Ismail Celik1, Saadettin Kılıçkap11Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
Objectives: Peripheral blood-based markers like the systemic inflammation index is (SII) could be valuable for melanoma patients treated with immune checkpoint inhibitors (ICIs), although the data is limited. We aimed to evaluate the association between the baseline SII with survival in ICI-treated melanoma patients. Methods: The data of 44 advanced adult melanoma patients treated with ICIs (ipilimumab or nivolumab) were retrospectively evaluated. The SII was calculated with the platelet*(neutrophil/lymphocyte) formula. The median value of SII as the cut-off point. The association between SII values and survival were evaluated with univariate and multivariate analyses. Results: The median age was 61 years (IQR 51-68), and 52.3% of the patients were male. During a median follow-up of 7.52 months, 35 patients died (79.5%), and 39 patients (88.6%) had any PFS event. The patients with higher SII values had decreased overall survival (OS) (11.203±2.491 vs. 5.520±2.063 months, p=0.015). In the multivariate analyses, including adjustments according to patient sex, age, and lactate dehydrogenase levels, patients with higher SII values had decreased OS (HR: 2.209, 95% CI: 1.105-4.417, p=0.025). Conclusion: In our experience, melanoma patients with higher SII values had poorer survival. The SII could be a valuable biomarker for prognosis estimation in ICI-treated melanoma patients. Keywords: Immunotherapy, melanoma, SII
Cite This Article
Guven D, Aktepe O, Yildirim H, Celik I, Kılıçkap S. Higher Systemic Immune-Inflammation Index (SII) Levels Are Associated With Poorer Survival In Immunotherapy-Treated Melanoma Patients. EJMI. 2021; 5(3): 409-413
Corresponding Author: Deniz Can Guven